Klin Farmakol Farm. 2021;35(1):35-39

Durvalumab in the treatment of non-small cell lung lung cancer

Ondřej Bílek
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

Non-small cell lung cancer (NSCLC) is in most of cases diagnosed as an advanced stage of the disease. Immunotherapy with anti-PD-1 and PD-L1 check-point inhibitors is currently a standard modality of the treatment algorithm. Durvalumab is a fully humanized IgGκ anti-PD-L1 monoclonal antibody. This article goal is to summarize the therapeutic results of durvalumab in NSCLC treatment.

Keywords: non‑small cell lung cancer, immunotherapy, durvalumab.

Published: April 9, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bílek O. Durvalumab in the treatment of non-small cell lung lung cancer. Klin Farmakol Farm. 2021;35(1):35-39.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie Zhoubných Nádorů v České Republice. [Online]. Dostupné z: Http:/ / www.svod.cz.
    2. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am. J. Clin. Oncol. 2016; 39(1): 98-106. https://doi.org/10.1097/COC.0000000000000239. Go to original source... Go to PubMed...
    3. Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, Bannister D, Dick E, Crawford N, Parmentier J, Alimzhanov M, Babcook JS, Foltz IN, Buchanan A, Bedian V, Wilkinson RW, McCourt M. Identification and Characterization of MEDI4736, an Antagonistic Anti‑PD‑L1 Monoclonal Antibody. Cancer Immunol Res 2015, 3 (9), 1052-1062. https://doi.org/10.1158/2326-6066.CIR-14-0191. Go to original source... Go to PubMed...
    4. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. Molecular Mechanism of PD-1/PD‑L1 Blockade via Anti‑PD‑L1 Antibodies Atezolizumab and Durvalumab. Sci Rep 2017, 7 (1), 5532. https://doi.org/10.1038/s41598-017-06002-8. Go to original source... Go to PubMed...
    5. Antonia SJ, Brahmer JR, Khleif S, Balmanoukian AS, Ou S‑HI, Gutierrez M, Kim D‑W, Kim S‑W, Ahn M‑J, Leach J, Jamal R, Jaeger D, Jerusalem G, Jin X, Gupta A, Antal J, Segal NH. Phase 1/2 Study of the Safety and Clinical Activity of Durvalumab in Patients with Non‑Small Cell Lung Cancer (NSCLC). Ann Oncol 2016; 27(suppl_6). https://doi.org/10.1093/annonc/mdw383. 16. Go to original source...
    6. Safety and clinical activity of durvalumab (MEDI4736), an anti‑PD‑L1 antibody, in treatment‑naïve patients with advanced non-small‑cell lung cancer. | Journal of Clinical Oncology https://ascopubs.org/doi/abs/10.1200/JCO.2016. 34. 15_suppl.9029 (accessed Dec 29, 2019).
    7. Garassino MC, Cho B‑C, Kim J‑H, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley‑Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA. ATLANTIC Investigators. Durvalumab as Third‑Line or Later Treatment for Advanced Non‑Small‑Cell Lung Cancer (ATLANTIC): An Open‑Label, Single‑Arm, Phase 2 Study. Lancet Oncol. 2018; 19(4): 521-536. https://doi.org/10.1016/S1470-2045(18)30144-X. Go to original source... Go to PubMed...
    8. Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn M‑J, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman A‑M, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S. MYSTIC Investigators. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First‑Line Treatment of Metastatic Non‑Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; 6(5): 661-674. https://doi.org/10.1001/jamaoncol.2020.0237. Go to original source... Go to PubMed...
    9. First‑line Durvalumab Improves Survival | ESMO https://www.esmo.org/Oncology‑News/First‑line‑Durvalumab‑Improves‑Survival‑Compared‑to‑Chemotherapy‑in‑Metastatic‑NSCLC (accessed Jan 3, 2020).
    10. Peters S, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn M‑J, Baas P, Dols MC, Smolin A, Vicente D, Moiseyenko V, Antonia SJ, Nakagawa K, Goldberg SB, Kim E, Raja R, Brohawn P, Clemett D, Thiyagarajah P, Scheuring U, Liu F, Rizvi N. Abstract CT074: Tumor Mutational Burden (TMB) as a Biomarker of Survival in Metastatic Non‑Small Cell Lung Cancer (MNSCLC): Blood and Tissue TMB Analysis from MYSTIC, a Phase III Study of First‑Line Durvalumab ± Tremelimumab vs Chemotherapy. Cancer Res 2019; 79(13 Supplement): CT074-CT074. https://doi.org/10.1158/1538-7445.AM2019-CT074. Go to original source... Go to PubMed...
    11. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat M‑C, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon J‑P. Meta‑Analysis of Concomitant versus Sequential Radiochemotherapy in Locally Advanced Non‑Small‑Cell Lung Cancer. J. Clin. Oncol. 2010; 28(13): 2181-2190. https://doi.org/10.1200/JCO.2009. 26. 2543. Go to original source...
    12. Formenti SC, Demaria S. Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift. J. Natl. Cancer Inst. 2013; 105(4): 256-265. https://doi.org/10.1093/jnci/djs629. Go to original source... Go to PubMed...
    13. Golden EB, Pellicciotta I, Demaria S, Barcellos‑Hoff MH, Formenti SC. The Convergence of Radiation and Immunogenic Cell Death Signaling Pathways. Front Oncol 2012; 2: 88. https://doi.org/10.3389/fonc.2012.00088. Go to original source... Go to PubMed...
    14. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing Radiation Inhibition of Distant Untreated Tumors (Abscopal Effect) Is Immune Mediated. Int. J. Radiat. Oncol. Biol. Phys. 2004; 58(3): 862-870. https://doi.org/10.1016/j.ijrobp.2003. 09. 012. Go to original source... Go to PubMed...
    15. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous Radiotherapy and the Clinical Activity and Toxicity of Pembrolizumab in the Treatment of Non‑Small‑Cell Lung Cancer: A Secondary Analysis of the KEYNOTE-001 Phase 1 Trial. Lancet Oncol. 2017; 18(7): 895-903. https://doi.org/10.1016/S1470-2045(17)30380-7. Go to original source... Go to PubMed...
    16. Faivre‑Finn C, Spigel DR, Senan S, Langer CJ, Raben D, Perez B, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz‑Ares L, Poole L, Wadsworth C, Dennis PA, Antonia SJ. 1363OEfficacy and Safety Evaluation Based on Time from Completion of Radiotherapy to Randomization with Durvalumab or Placebo in Pts from PACIFIC. Ann Oncol 2018; 29(suppl_8). https://doi.org/10.1093/annonc/mdy291. Go to original source...
    17. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre‑Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S. Metastatic Non‑Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‑Up. Ann. Oncol. 2019; 30(5): 863-870. https://doi.org/10.1093/annonc/mdy474. Go to original source... Go to PubMed...
    18. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y‑C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz‑Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M. PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non‑Small‑Cell Lung Cancer. N. Engl. J. Med. 2017; 377(20): 1919-1929. https://doi.org/10.1056/NEJMoa1709937. Go to original source... Go to PubMed...
    19. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz‑Ares L, Faivre‑Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ. Three‑Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC‑Update from PACIFIC. J Thorac Oncol 2020; 15(2): 288-293. https://doi.org/10.1016/j.jtho.2019. 10. 002. Go to original source... Go to PubMed...
    20. Faivre‑Finn C, Vicente D, Kurata T, Planchard D, Paz‑Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu Y‑L, Gray JE, Özgüroğlu M, Lee KH, Newton M, Wang L, Thiyagarajah P, Antonia SJ. LBA49 Durvalumab after Chemoradiotherapy in Stage III NSCLC: 4-Year Survival Update from the Phase III PACIFIC Trial. Annals of Oncology 2020; 31: S1178-S1179. https://doi.org/10.1016/j.annonc.2020. 08. 2281. Go to original source...
    21. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y‑C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz‑Ares L, de Castro Carpeño J, Faivre‑Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379(24): 2342-2350. https://doi.org/10.1056/NEJMoa1809697. Go to original source... Go to PubMed...
    22. Faivre‑Finn C, Spigel DR, Senan S, Langer CJ, Raben D, Perez B, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz‑Ares L, Poole L, Wadsworth C, Dennis PA, Antonia SJ. 1363OEfficacy and Safety Evaluation Based on Time from Completion of Radiotherapy to Randomization with Durvalumab or Placebo in Pts from PACIFIC. Ann Oncol 2018; 29(suppl_8). https://doi.org/10.1093/annonc/mdy291. Go to original source...
    23. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y‑C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz‑Ares L, de Castro Carpeño J, Faivre‑Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379(24): 2342-2350. https://doi.org/10.1056/NEJMoa1809697. Go to original source... Go to PubMed...
    24. European Medical Agency. Imfinzi: Summary of Product Characteristics, Https://www.Ema.Europa.Eu/En/Documents/Product‑Inf.
    25. FDA Approves Additional Dosing Option of Durvalumab for Stage III NSCLC, Advanced Bladder Cancer https://www.cancernetwork.com/view/fda‑approves‑additional‑dosing‑option‑of‑durvalumab‑for‑stage‑iii‑nsclc‑advanced‑bladder‑cancer (accessed Nov 29, 2020).
    26. Imfinzi‑Epar‑Product‑Information_cs.Pdf.
    27. Durm GA, Althouse SK, Sadiq AA, Jalal SI, Jabbour S, Zon R, Kloecker GH, Fisher WB, Reckamp KL, Kio EA, Langdon RM, Adesunloye B, Gentzler RD, Hanna NH. Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III Non‑Small Cell Lung Cancer: Hoosier Cancer Research Network LUN 14-179. JCO 2018; 36(15_suppl): 8500-8500. https://doi.org/10.1200/JCO.2018. 36. 15_suppl.8500. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.